The spinout, which has developed a portable real-time DNA and RNA sequencer, has attracted $140m in funding from investors including GIC, China Construction Bank and Hostplus.

The University College London gene therapy spinout has completed a series B round backed by the institution's UCL Technology Fund.

Medtronic, Novartis and SinoPharm are among the investors in a series B round for Harvard spinout Semma Therapeutics, which is working on a treatment for patients suffering from diabetes.

Immunotherapy developer Arcus Biosciences, backed by Stanford University, has raised series C funding from a GV-led consortium that included Celgene and Taiho.

The Chinese Academy Of Sciences spinout, which is developing deep learning chipsets, has secured $100m in a series A round featuring CAS Investment.

Bayer Lifescience Center joined Versant Ventures to launch BlueRock, a Kyoto spinout that will develop stem cell treatments for cardiovascular diseases and neurodegenerative disorders.

The spinout has raised additional funding after announcing earlier this month that it had become the first company to sequence multiple human genomes using portable technology.

Celgene, Novartis, GV and Taiho Ventures are among the backers that provided the funding for the Stanford-backed immuno-oncology company over two rounds.

The pharmaceutical company has boosted its stake in mRNA drug developer and strategic partner Moderna to 9%, lifting Moderna's overall funding to at least $790m.